TECH vs. MRNA

Last updated Apr 2, 2026

Compare and contrast key facts about Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA).

Performance

TECH vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

TECH vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
TECH Bio-Techne Corporation	-8.94%	-17.89%	-6.13%	-6.49%	-35.69%	63.40%	45.40%	52.67%	-7.36%
MRNA Moderna, Inc.	69.65%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-17.90%

Fundamentals

Market Cap TECH : $8.38B MRNA : $19.61B
EPS TECH : $0.52 MRNA : -$7.24
PS Ratio TECH : 6.86 MRNA : 10.04
PB Ratio TECH : 4.12 MRNA : 2.27
Total Revenue (TTM) TECH : $1.22B MRNA : $1.94B
Gross Profit (TTM) TECH : $792.76M MRNA : $274.00M
EBITDA (TTM) TECH : $173.06M MRNA : -$2.61B

Returns By Period

In the year-to-date period, TECH achieves a -8.94% return, which is significantly lower than MRNA's 69.65% return.

TECH

• 1D: 2.33%
• 1M: -7.51%
• YTD: -8.94%
• 6M: -10.51%
• 1Y: -6.20%
• 3Y*: -9.86%
• 5Y*: -10.85%
• 10Y*: 9.09%

MRNA

• 1D: -1.52%
• 1M: -5.33%
• YTD: 69.65%
• 6M: 81.27%
• 1Y: 84.20%
• 3Y*: -31.19%
• 5Y*: -17.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TECH vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TECH

TECH Risk / Return Rank: 32
TECH Sharpe Ratio Rank: 34
TECH Sortino Ratio Rank: 31
TECH Omega Ratio Rank: 31
TECH Calmar Ratio Rank: 32
TECH Martin Ratio Rank: 30

MRNA

MRNA Risk / Return Rank: 77
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 78
MRNA Omega Ratio Rank: 73
MRNA Calmar Ratio Rank: 78
MRNA Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TECH vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TECH	MRNA	Difference
Sharpe ratio Return per unit of total volatility	-0.14	1.28	-1.42
Sortino ratio Return per unit of downside risk	0.11	2.02	-1.91
Omega ratio Gain probability vs. loss probability	1.01	1.24	-0.22
Calmar ratio Return relative to maximum drawdown	-0.26	2.15	-2.42
Martin ratio Return relative to average drawdown	-0.63	4.44	-5.08
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TECH vs. MRNA - Sharpe Ratio Comparison

The current TECH Sharpe Ratio is -0.14, which is lower than the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of TECH and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TECH	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.14	1.28	-1.42
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	-0.27	-0.03
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.34	0.20	+0.14

Correlation

The correlation between TECH and MRNA is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TECH vs. MRNA - Dividend Comparison

TECH's dividend yield for the trailing twelve months is around 0.60%, while MRNA has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
TECH Bio-Techne Corporation	0.60%	0.54%	0.56%	0.41%	0.39%	0.25%	0.40%	0.58%	0.88%	0.99%	1.24%	1.42%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

TECH vs. MRNA - Drawdown Comparison

The maximum TECH drawdown since its inception was -74.39%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for TECH and MRNA.

Drawdown Indicators

	TECH	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-74.39%	-95.38%	+20.99%
Max Drawdown (1Y) Largest decline over 1 year	-31.52%	-35.51%	+3.99%
Max Drawdown (5Y) Largest decline over 5 years	-64.78%	-95.38%	+30.60%
Max Drawdown (10Y) Largest decline over 10 years	-64.78%	—	—
Current Drawdown Current decline from peak	-59.46%	-89.67%	+30.21%
Average Drawdown Average peak-to-trough decline	-23.92%	-55.87%	+31.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.01%	17.21%	-4.20%

Volatility

TECH vs. MRNA - Volatility Comparison

The current volatility for Bio-Techne Corporation (TECH) is 11.53%, while Moderna, Inc. (MRNA) has a volatility of 22.27%. This indicates that TECH experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TECH	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.53%	22.27%	-10.74%
Volatility (6M) Calculated over the trailing 6-month period	27.31%	50.95%	-23.64%
Volatility (1Y) Calculated over the trailing 1-year period	44.33%	66.40%	-22.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	37.05%	66.59%	-29.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.95%	72.29%	-39.34%

Financials